A Clinical Study on the Effect of Hibon-40(R): Riboflavin tetrabutyrate.

Joo, Choun Ki; Kim, Man Soo; Kim, Jae Ho

Original Article

Journal of the Korean Ophthalmological Society 1986;27(3):321-325.
Published online March 1, 1986.

A Clinical Study on the Effect of Hibon-40(R): Riboflavin tetrabutyrate.

Choun Ki Joo, Man Soo Kim, Jae Ho Kim

Department of Ophthalmology, Kangnam St. Mary's Hospital, Catholic Medical College, Seoul, Korea.

안과영역에서의 Hibon-40(R) ( Riboflavin tetrabutyrate ) 의 치료효과

김재호(Jae Ho Kim),김만수(Man Soo Kim),주천기(Chun Ki Joo)

Abstract

Diseases caused by arteriosclerosis now occupy the first rank of the causes of death; they tend to increase further, and the countermeasure for adults' diseases is now noticed as one of big social problems. This study was devised to observe the effect of riboflavin tetrabutyrate on themetabolic changes in arteriosclerotic retinopathy, diabetic retinopathy, cataract and external eye diseases. After each case was treated three times daily for up to 13 weeks with riboflavin terabutyrate 120mg, we examined the visual acuity, retina changes, and cholesterol level at each visit. The results were as follows: 1. In arteriosclerotic retinopathy, visual improvement is noted in 44% of 18 cases and serum cholesterol level is decreased by 30.9mg/dl in average. 2. In diabetic retinopathy, visual improvement is noted in 37.5% of 16 cases and serum cholesterol level is decreased by 21.9mg/dl in average. 3. In cataract, visual improvement is noted in 8% of 12 cases and serum cholesterol level is reduced by 12.1mg/dl in average. 4. In external eye diseases, the symptoms and signs are much relieved.